Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending July 2011. The report serves as a notification of transactions involving directors, persons discharging managerial responsibility, or connected persons, specifically regarding the GlaxoSmithKline Performance Share Plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on a specific share transaction rather than general financial performance.
Material Changes
The filing reports an increase in the interest of Mr. D E Troy in Ordinary share ADRs. This transaction occurred on July 12, 2011, at a price of $43.91 per ADR, resulting from the re-investment of the dividend paid to shareholders on July 7, 2011. The total number of ADRs involved in this notification is 272.446.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is a compliance notification under Disclosure and Transparency Rule 3.1.4R(1)(a).
Key Facts for Investor Verification
- Transaction Date: July 12, 2011
- Individual Involved: Mr. D E Troy
- Transaction Type: Increase in ADR interest via dividend re-investment
- Price per ADR: $43.91
- Volume: 272.446 ADRs
- Dividend Date: July 7, 2011